Surrozen (SRZN) Cash from Financing Activities (2020 - 2026)
Surrozen (SRZN) recorded quarterly Cash from Financing Activities of $30.3 million in Q1 2026, up 119.72% quarter-over-quarter from $13.8 million in Q4 2025, and down 60.36% on a YoY basis from $76.4 million in Q1 2025.
Surrozen (SRZN) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Surrozen's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $30.3 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 60.36% year-over-year to $30.3 million; the TTM figure through Mar 2026 stood at $38.9 million (down 57.92% YoY), while the FY2025 annual figure was $85.1 million, up 425.79% from the prior year.
- Cash from Financing Activities was $30.3 million for Q1 2026 at Surrozen, up from $13.8 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $76.4 million in Q1 2025 to a low of -$5.1 million in Q2 2025.
- Historically, Cash from Financing Activities has averaged $8.6 million across 5 years, with a median of $9000.0 in 2025.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities plunged 1703.14% in 2022, then jumped 15043.96% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$2.5 million in 2022, then surged by 105.53% to $141000.0 in 2023, then slumped by 35.46% to $91000.0 in 2024, then surged by 15043.96% to $13.8 million in 2025, then soared by 119.72% to $30.3 million in 2026.
- The last three Cash from Financing Activities figures came in at $30.3 million (Q1 2026), $13.8 million (Q4 2025), and $9000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 85,464.43 |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | 30.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.28 Mn |
| Mar 31, 2026 | 30.28 Mn |
| Dec 31, 2025 | 13.78 Mn |
| Dec 31, 2025 | 13.78 Mn |
| Sep 30, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | -5.12 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Mar 31, 2025 | 76.39 Mn |
| Mar 31, 2025 | 76.39 Mn |
| Dec 31, 2024 | 91,000.00 |
| Dec 31, 2024 | 91,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | 16.09 Mn |
| Jun 30, 2024 | 16.09 Mn |
| Dec 31, 2023 | 141,000.00 |
| Dec 31, 2023 | 141,000.00 |
| Sep 30, 2023 | -13,000.00 |
| Sep 30, 2023 | -13,000.00 |